Tag
A long-term follow-up of the SPRINT trial shows no significant difference in recurrent stroke or mortality rates between initial low and moderate fixed doses of hydroxyurea in sickle cell disease, emphasizing event clustering within the fir
The phase 3 SAFFRON trial demonstrated that osimertinib combined with savolitinib significantly improves progression-free and overall survival versus platinum-pemetrexed chemotherapy in advanced EGFR-mutated NSCLC harboring MET overexpressi
Saroglitazar, a dual PPAR α/γ agonist, demonstrated significant biochemical improvement and ALP normalization in primary biliary cholangitis patients refractory or intolerant to UDCA, with favorable safety over 52 weeks in a phase 2b/3 tria
Sacituzumab tirumotecan combined with pembrolizumab significantly improves progression-free survival in PD-L1-negative advanced nonsquamous NSCLC compared to chemotherapy plus pembrolizumab, offering a promising new treatment standard with
In a phase 2 trial, oral QY201 significantly improved skin outcomes in moderate-to-severe atopic dermatitis with favorable safety, supporting further phase 3 evaluation.
The FIBRONEER-ILD trial demonstrates nerandomilast’s potential to slow lung function decline and reduce mortality in patients with autoimmune-related progressive pulmonary fibrosis, with a favorable safety profile.
Ivarmacitinib, a selective JAK1 inhibitor, demonstrated rapid efficacy and immune remodeling in palmoplantar pustulosis over 12 weeks, with favorable safety and potential biomarkers for response stratification.
This RCT assesses clinical, radiographic, histological, and patient-reported outcomes of soft-tissue augmentation with connective tissue grafts and volume-stable collagen matrices during implant placement in the aesthetic zone.
This phase 2b trial demonstrates that oral icotrokinra, targeting the interleukin-23 receptor, significantly improves clinical outcomes in moderate to severe ulcerative colitis compared to placebo.
This review synthesizes current evidence on pulse versus nonpulse corticosteroid therapy in AE-IPF, contextualizing the SAFER trial findings within prior studies and clinical guidelines to guide management and future research.
A multi-center RCT assessing the adjunctive use of the Paro-ComPas app in periodontal care found no significant overall benefit, though moderate app engagement showed potential for improved plaque control.
The phase 2 MIRA trial shows sonelokimab, an IL-17A/F-inhibiting nanobody, significantly improves outcomes in moderate-to-severe hidradenitis suppurativa with good tolerability compared to placebo.
Transcatheter tricuspid-valve repair plus medical therapy significantly improves survival, reduces heart failure hospitalizations, and enhances quality of life in patients with severe tricuspid regurgitation compared to medical therapy alon
A large randomized trial assessing whether adding a blood-based multicancer early-detection test to usual care reduces late-stage cancer diagnoses found no significant difference in stage III or IV cancers but observed a trend toward fewer
This phase 2 trial assessed SAR443820, a RIPK1 inhibitor, in ALS patients; it showed no clinical efficacy and increased hepatic side effects, indicating limited therapeutic potential in ALS.
Dapirolizumab pegol, a CD40 ligand inhibitor, significantly improves disease activity in moderate-to-severe SLE over 48 weeks when added to standard care, supported by robust phase 3 trial data and pharmacokinetic findings.
The phase Ib ELEVATE study demonstrates that cusatuzumab combined with venetoclax and azacitidine offers a promising tolerable and effective frontline therapy for patients with newly diagnosed acute myeloid leukemia ineligible for intensive
A pilot randomized trial comparing targeted temperature management at 35°C versus normothermia in intubated heatstroke patients showed no survival or neurological benefit from hypothermia but increased gastrointestinal injury and arrhythmia
A randomized, double-blind, placebo-controlled trial demonstrates gabapentin’s significant efficacy and acceptable safety for treating cough in IPF, supporting its clinical use amid limited alternatives.
A randomized clinical trial comparing individualized versus standard blood pressure control during mechanical thrombectomy for ischemic stroke showed no significant difference in 90-day functional outcomes or safety.
